恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效分析(1)
摘 要：目的 探讨恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效和安全性。方法 本研究选取2015年2月～2016年7月我院收治的失代偿期乙型肝炎肝硬化初治患者120例，根据入院顺序的单双号分为观察组和对照组，每组60例。两组均给予常规治疗，在此基础上，对照组给予拉米夫定治疗，观察組给予恩替卡韦治疗，50周后，对比两组患者的Child-Pugh积分、血清病毒学HBV-DNA和PTA的数据。结果 治疗50周后，两组患者治疗指标均有所好转，观察组Child-Pugh 积分、HBV-DNA、PTA分别为(9.48±1.87)分、(2.87±0.12)log copies/ml、(0.79±0.11)%，优于对照组的(5.76±1.09)分、(4.58±0.46)log copies/ml、(0.61±0.12)%，差异均具有统计学意义(P<0.05)。结论 恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效满意，值得临床推广应用。
关键词：恩替卡韦；抗病毒；失代偿期；乙肝肝硬化
, http://www.100md.com
中图分类号：R512.62；R575.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.10.042
文章编号：1006-1959(2018)10-0129-02
Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis
TANG Ping-yang
(Department of Hepatology，Subject Four，Cangzhou Infectious Disease Hospital，Cangzhou 061001，Hebei，China)
Abstract：Objective To investigate the clinical efficacy and safety of entecavir antiviral therapy in patients with decompensated hepatitis B liver cirrhosis.Methods In this study，120 patients with decompensated hepatitis B cirrhosis who were treated in our hospital from February 2015 to July 2016 were selected and divided into an observation group and a control group according to the odd and even numbers of the admission order.60 cases in each group.Both groups received conventional treatment.On this basis，the control group received lamivudine treatment.The observation group received entecavir treatment.After 50 weeks，the Child-Pugh scores， serum virological HBV-DNA and PTA data were compared between the two groups.Results After 50 weeks of treatment，the treatment indicators of both groups improved.The Child-Pugh score，HBV-DNA，and PTA in the observation group were(9.48±1.87) points，(2.87±0.12)log copies/ml，(0.79±0.11)%，better than the control group(5.76±1.09)points，(4.58±0.46)log copies/ml，(0.61±0.12)%， the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of entecavir antiviral therapy in patients with decompensated hepatitis B cirrhosis is satisfactory and worthy of clinical application.
, 百拇医药
Key words：Entecavir；Antiviral；Decompensation；Hepatitis B cirrhosis
我国是肝炎大国，其中以乙型肝炎为主。肝炎的危险三部曲是肝炎、肝硬化、肝癌。如何阻断肝炎的发展进程是治疗肝炎的关键[1]。失代偿期乙型肝炎肝硬化是乙肝发展的不良预后，是终末期的肝病，往往由于多种并发症而危及生命。恩替卡韦是一种口服的抗病毒药，属于核苷类似物，据相关研究显示，恩替卡韦治疗乙肝疗效肯定[2]。但是对于失代偿期的肝硬化患者，应用恩替卡韦是否有效值得临床研究[5]，本研究选取我院收治的失代偿期乙型肝炎肝硬化初治患者120例作为研究对象探讨了恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床效果，取得了满意的结果，总结报告如下。
1资料与方法
1.1一般资料 本研究选取2015年2月～2016年7月沧州市传染病医院肝病四科收治的失代偿期乙型肝炎肝硬化初治患者120例作为研究对象，本研究经医院伦理会批准。根据入院顺序的单双号分为对照组和观察组，每组60例。对照组中，男39例，女21例，年龄45～73岁，平均年龄(52.29±4.34)岁，病程1～11年，平均病程(4.29±1.37)年；观察组中，男40例，女20例，年龄43～74岁，平均年龄(53.52±4.65)岁，病程1～13年，平均病程(4.78±1.65)年。两组患者的性别、年龄、病程等资料相比，差异具有统计学意义(P>0.05)，具有可比性。, http://www.100md.com(唐平阳)
关键词：恩替卡韦；抗病毒；失代偿期；乙肝肝硬化
, http://www.100md.com
中图分类号：R512.62；R575.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.10.042
文章编号：1006-1959(2018)10-0129-02
Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis
TANG Ping-yang
(Department of Hepatology，Subject Four，Cangzhou Infectious Disease Hospital，Cangzhou 061001，Hebei，China)
Abstract：Objective To investigate the clinical efficacy and safety of entecavir antiviral therapy in patients with decompensated hepatitis B liver cirrhosis.Methods In this study，120 patients with decompensated hepatitis B cirrhosis who were treated in our hospital from February 2015 to July 2016 were selected and divided into an observation group and a control group according to the odd and even numbers of the admission order.60 cases in each group.Both groups received conventional treatment.On this basis，the control group received lamivudine treatment.The observation group received entecavir treatment.After 50 weeks，the Child-Pugh scores， serum virological HBV-DNA and PTA data were compared between the two groups.Results After 50 weeks of treatment，the treatment indicators of both groups improved.The Child-Pugh score，HBV-DNA，and PTA in the observation group were(9.48±1.87) points，(2.87±0.12)log copies/ml，(0.79±0.11)%，better than the control group(5.76±1.09)points，(4.58±0.46)log copies/ml，(0.61±0.12)%， the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of entecavir antiviral therapy in patients with decompensated hepatitis B cirrhosis is satisfactory and worthy of clinical application.
, 百拇医药
Key words：Entecavir；Antiviral；Decompensation；Hepatitis B cirrhosis
我国是肝炎大国，其中以乙型肝炎为主。肝炎的危险三部曲是肝炎、肝硬化、肝癌。如何阻断肝炎的发展进程是治疗肝炎的关键[1]。失代偿期乙型肝炎肝硬化是乙肝发展的不良预后，是终末期的肝病，往往由于多种并发症而危及生命。恩替卡韦是一种口服的抗病毒药，属于核苷类似物，据相关研究显示，恩替卡韦治疗乙肝疗效肯定[2]。但是对于失代偿期的肝硬化患者，应用恩替卡韦是否有效值得临床研究[5]，本研究选取我院收治的失代偿期乙型肝炎肝硬化初治患者120例作为研究对象探讨了恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床效果，取得了满意的结果，总结报告如下。
1资料与方法
1.1一般资料 本研究选取2015年2月～2016年7月沧州市传染病医院肝病四科收治的失代偿期乙型肝炎肝硬化初治患者120例作为研究对象，本研究经医院伦理会批准。根据入院顺序的单双号分为对照组和观察组，每组60例。对照组中，男39例，女21例，年龄45～73岁，平均年龄(52.29±4.34)岁，病程1～11年，平均病程(4.29±1.37)年；观察组中，男40例，女20例，年龄43～74岁，平均年龄(53.52±4.65)岁，病程1～13年，平均病程(4.78±1.65)年。两组患者的性别、年龄、病程等资料相比，差异具有统计学意义(P>0.05)，具有可比性。, http://www.100md.com(唐平阳)